Bio2 Technologies (Woburn, Mass.) has raised about $4.3 million as it continues with a clinical trial of its Vitrium resorbable orthopedic biomaterial for musculoskeletal surgery. Bio2 had sought to raise $6.5 million in the funding round, according to a Form D filed Sept. 6 with the U.S. Securities and Exchange Commission. Made of bioactive glass, […]
Bio2 Technologies
FDA awards priority review status to Cohera Medical’s surgical sealant Sylys | Regulatory news for the week of December 22, 2014
Mass. Life Sciences Center awards $4M in loans to 4 local startups
The Massachusetts Life Sciences Center awarded a total of nearly $4 million in loans to 4 Boston-area life sciences startups – Arch Therapeutics, Bio2 Technologies, ImmuneXcite and MedicaMetrix each received loans of up to $1 million.
The quasi-public agency’s flagship investment program supports and "de-risks" early-stage companies by providing loans to match other sources of capital as a part of Massachusetts’ 10 year, $1 billion Life Sciences Initiative.
Device tax spurs Hill-Rom to lay off 200 | Wall Street Beat
Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.
Bio2 adds $1.1 million to its coffers
Bio2 Technologies Inc. raised $1.1 million in an equity offering, according to a regulatory filing.
The Woburn, Mass.-based orthopedic bio-scaffold developer opened the sale June 28, making $2 million in equity available in minimum purchases of $20,000. Eighteen investors had ponied up for the offering as of the July 1 filing.
